Vile R - Search Results

1

Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.

Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R. Crittenden M, et al. Among authors: vile r. Cancer Res. 2003 Jun 15;63(12):3173-80. Cancer Res. 2003. PMID: 12810645

2

Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.

Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Vile RG, et al. Cancer Res. 1994 Dec 1;54(23):6228-34. Cancer Res. 1994. PMID: 7954471

3

In vitro and in vivo targeting of gene expression to melanoma cells.

Vile RG, Hart IR. Vile RG, et al. Cancer Res. 1993 Mar 1;53(5):962-7. Cancer Res. 1993. PMID: 8439971

4

Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter.

Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ. Vile RG, et al. Virology. 1995 Dec 1;214(1):307-13. doi: 10.1006/viro.1995.9923. Virology. 1995. PMID: 8525635 Free article.

5

Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line.

Chong H, Vile RG. Chong H, et al. Among authors: vile rg. Gene Ther. 1996 Jul;3(7):624-9. Gene Ther. 1996. PMID: 8818650

6

Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity.

Chong H, Hutchinson G, Hart IR, Vile RG. Chong H, et al. Among authors: vile rg. Hum Gene Ther. 1996 Sep 10;7(14):1771-9. doi: 10.1089/hum.1996.7.14-1771. Hum Gene Ther. 1996. PMID: 8886848

7

New therapeutic approaches based on gene transfer techniques.

Chong H, Vile RG. Chong H, et al. Among authors: vile rg. Springer Semin Immunopathol. 1996;18(2):149-70. doi: 10.1007/BF00820663. Springer Semin Immunopathol. 1996. PMID: 8908697 Review. No abstract available.

8

Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Vile RG, Chong H. Vile RG, et al. Cancer Metastasis Rev. 1996 Sep;15(3):351-64. doi: 10.1007/BF00046347. Cancer Metastasis Rev. 1996. PMID: 9034596 Review.

9

Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression.

Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Vile RG, et al. Int J Cancer. 1997 Apr 10;71(2):267-74. doi: 10.1002/(sici)1097-0215(19970410)71:2<267::aid-ijc23>3.0.co;2-d. Int J Cancer. 1997. PMID: 9139853

10

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells.

Vile RG, Diaz RM, Castleden S, Chong H. Vile RG, et al. Biochem Soc Trans. 1997 May;25(2):717-22. doi: 10.1042/bst0250717. Biochem Soc Trans. 1997. PMID: 9191190 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters